<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677297</url>
  </required_header>
  <id_info>
    <org_study_id>DPU/R &amp; R (D)/ 98(10)/ 16</org_study_id>
    <nct_id>NCT03677297</nct_id>
  </id_info>
  <brief_title>&quot;Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects&quot;</brief_title>
  <official_title>Comparative Evaluation of Treatment Of Infrabony Defects With and Without 1.2% Rosuvastatin Gel: In-Vivo Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. D. Y. Patil Dental College &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. D. Y. Patil Dental College &amp; Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study aims to evaluate clinical and radiographic effectiveness of 1.2% Rosuvastatin gel in&#xD;
      the treatment of Infrabony defects in chronic periodontitis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Source from where the patients will be selected:&#xD;
&#xD;
      10 patients with chronic periodontitis having two or more infrabony defects will be selected&#xD;
      from the Outpatient section of Dept. of Periodontology, Dr. D. Y. Patil Dental College and&#xD;
      Hospital, Pimpri, Pune - 18.&#xD;
&#xD;
      A detailed clinical examination, case history and written consent will be obtained from all&#xD;
      the participants.&#xD;
&#xD;
      Before surgery, each patient will be given careful instructions regarding proper oral hygiene&#xD;
      measures. A full-mouth phase I therapy will be performed. A periodontal re-evaluation will be&#xD;
      performed after 4 to 6 weeks of phase 1 therapy to confirm the desired sites for the study.&#xD;
      The selected sites will be divided randomly by using a Sequentially numbered, opaque, sealed&#xD;
      envelopes (SNOSE) randomization into control and test sites. The control site will be treated&#xD;
      with Access Flap Surgery (AFS), whereas test sites will be treated with AFS and 1.2%&#xD;
      Rosuvastatin gel. Suitable antibiotics and analgesics will be prescribed along with&#xD;
      Chlorhexidine digluconate rinses (0.2%) twice daily for 14 days. Patients will be examined at&#xD;
      4 weeks, 3 and 6 month after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone fill</measure>
    <time_frame>6 months</time_frame>
    <description>Radiographic parameter measuring distance from cemento-enamel junction to the base of the defect.&#xD;
Difference in the measurement at the end of 6 months shows the amount of bone fill</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing depth</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in this parameter is desired at the end of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative attachment level</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in this parameter at the end of 6 months shows gain in attachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plaque index</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in plaque index at the end of 6 months shows improvement in gingival health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding index</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in bleeding index at the end of 6 months shows improvement in gingival health</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Adult Periodontitis</condition>
  <arm_group>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2% Rosuvastatin Gel. Insertion in infrabony defects once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No intervention used on control site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel</description>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>No intervention used on Control site</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age group between 30-50 years&#xD;
&#xD;
          -  Probing pocket depth ≥ 5mm following initial therapy.&#xD;
&#xD;
          -  Suitable interproximal angular infrabony defects of ≥3mm.&#xD;
&#xD;
          -  Involved teeth should be vital and asymptomatic.&#xD;
&#xD;
          -  Systemically healthy patients.&#xD;
&#xD;
          -  Patients who demonstrate acceptable oral hygiene prior to access flap surgery.&#xD;
&#xD;
          -  Patients agreed to sign informed consent and willing to return for the follow up&#xD;
             visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic statin therapy&#xD;
&#xD;
          -  Known or suspected allergy to the statin group&#xD;
&#xD;
          -  Allergy to sulfur containing drugs&#xD;
&#xD;
          -  History of aggressive periodontitis.&#xD;
&#xD;
          -  Presence of gingival recession at the surgical site.&#xD;
&#xD;
          -  Mobility of study teeth ≥ grade I.&#xD;
&#xD;
          -  Use of tobacco in any form.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  patients who have received any anti-inflammatory drugs and antibiotics in the previous&#xD;
             six months.&#xD;
&#xD;
          -  H/O osteoporosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sukhada D Deo, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. D. Y. Patil Dental College &amp; Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sukhada Deo</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. D. Y. Patil Dental College &amp; Hospital</investigator_affiliation>
    <investigator_full_name>DR. SUKHADA DEO</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Intervention Study</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

